Healthdirect Australia is not responsible for the content and advertising on the external website you are now entering.
Olumiant TM
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional. Always read the label. If symptoms persist see your healthcare professional.
Active ingredients: baricitinib
Brand name
(ARTG)
: OLUMIANT baricitinib 2 mg film-coated tablet blister packDownload the Consumer Medicine Information Leaflet
Download consumer medicine information leaflet (pdf) from the Therapeutic Goods Administration (TGA) website
What this medicine is used for
(ARTG)
Rheumatoid Arthritis,OLUMIANT is indicated for the treatment of moderate to severe active rheumatoid arthritis (RA) in adult patients who have responded inadequately, or who are intolerant, to one or more DMARDs.,OLUMIANT can be taken as monotherapy or in combination with cDMARDs, including methotrexate (MTX).,Atopic Dermatitis,OLUMIANT is indicated for the treatment of moderate to severe atopic dermatitis (AD) in adult patients who are candidates for systemic therapy.,Alopecia Areata,OLUMIANT is indicated for the treatment of severe alopecia areata (AA) in adult patients in whom other treatments have failed or are not appropriate and no spontaneous improvement is observed (see section 5.1 Pharmacodynamic properties; Clinical trials).
How to use this medicine
(ARTG)
This medicine contains one component only.
Component :
- Tablet, film coated
- Oral
- Light pink, oblong tablet debossed with "Lilly" script on one side and "2" on the other. Tablets contain a recessed area on each face of the tablet surface.
Storage conditions
(ARTG)
- Store below 30 degrees Celsius
- Store in Original Container
- Shelf lifetime is 3 Years.
- Store below 30 degrees Celsius
- Store in Original Container
- Shelf lifetime is 3 Years.
Do I need a prescription ?
(ARTG)
These medicine packs are available from a pharmacist and requires a prescription. It is
- 28 pack
- 7 pack
Pregnant or planning a pregnancy ?
(AHT)
For the active ingredient baricitinib
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
This medicine is under additional monitoring as it is new or being used in a different way. You can help identify new safety information by reporting any side effects you may get.
- You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems.
- For more information on the Black Triangle Scheme and how to report side effects, see www.tga.gov.au/black-triangle-scheme
Need more information?
These trusted information partners have more on this topic.
Top results
Olumiant - NPS MedicineWise
Please read this leaflet carefully before you start using Olumiant
Read more on NPS MedicineWise website
New safety warning for medicines used in arthritis and other inflammatory conditions | Therapeutic Goods Administration (TGA)
A safety warning has been added to a class of medicines called Janus Kinase inhibitors used for chronic inflammatory conditions.
Read more on TGA – Therapeutic Goods Administration website
What you need to know about COVID-19 - Immunisation Coalition
What you need to know about COVID-19 so you can protect yourself, your friends, family and the rest of the community.
Read more on Immunisation Coalition website
Top results
New safety warning for medicines used in arthritis and other inflammatory conditions | Therapeutic Goods Administration (TGA)
A safety warning has been added to a class of medicines called Janus Kinase inhibitors used for chronic inflammatory conditions.
Read more on TGA – Therapeutic Goods Administration website
